“These pre-clinical results confirm that all constructs are immunogenic as measured by IgG antibodies in serum, and we observed a robust boosting effect after the second dose.” In January 2020, Vaxart initiated a program to develop a COVID-19 vaccine based on its VAASTTM oral vaccines platform. The Company is currently evaluating multiple vaccine candidates in its preclinical models.
As the fallout from the coronavirus pandemic continues, the search for a vaccine is not slowing down.
“This has been a busy quarter at Vaxart, as we have focused on developing a vaccine candidate for COVID-19,” said Wouter Latour, MD, chief executive officer of Vaxart Inc. “We believe our oral tablet vaccine could be an important tool to help protect the global population from COVID-19.” Vaxart had cash of $29.9 million as of March 31, 2020. Vaxart received a total of $10.3 million from warrant exercises during the quarter.
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart's oral vaccine candidate for COVID-19.
It was inevitable, but is it a smart way to invest? New ETFs that focus on companies that will benefit from the health and economic crises are loading up on already-pricey dotcom and biotech shares.
“In January we pivoted to COVID-19, and we are now on track to start a first Phase 1 study in the second half of this year with our oral tablet vaccine,” said Wouter Latour, MD, chief executive officer of Vaxart. “We are developing a state-of-the-art gene-based vaccine utilizing our proprietary vector platform, and the lead candidate vaccines performed well in preclinical testing, generating very high levels of antibodies.”
COVID-19 has boosted the fortunes of several previously unknown biotechs. Case in point: Since the turn of the year Vaxart (VXRT) stock has shot up by a sky scraping 680%, on the back of its possible COVID-19 vaccine.The surge has continued this week following an announcement that Vaxart’s oral COVID-19 vaccine program exhibited promising preclinical data. Specifically, the company reported that a number of its vaccine candidates resulted in immune responses in 100% of tested animals following a single dose. Furthermore, two weeks after the first vaccination, data indicated that all animals given one of the vaccines had IgG anti-SARS CoV-2 antibodies. In comparison to untreated controls, the antibody responses were statistically significant in all vaccinated groups.Vaxart began preclinical studies for a COVID-19 vaccine in January, basing the program on its VAAST oral vaccines platform. The latest results compare well with the company’s oral influenza vaccine.The announcement follows another positive recent development. In March, Vaxart signed a development agreement with Emergent BioSolutions. Emergent is expected to manufacture Vaxart’s vaccine candidate, in preparation for a Phase 1 clinical study, anticipated to go ahead in 2H20.H.C. Wainwright’s Vernon Bernardino believes that despite the early stage of development, the results indicate noteworthy progress in identifying a lead candidate for a clinical trial.Additionally, the 5-star analyst said, “In our view, the positive results were no surprise, given the favorable clinical profile observed in the company’s oral influenza vaccine candidate. We believe these preclinical results are in line with those for Vaxart’s oral influenza vaccine, which was protective in a clinical Phase 2 efficacy study… We believe the mucosal and systemic immunity observed, coupled with its oral, room temperature-stable tablet form, could offer logistical advantages over injectables during pandemic vaccination campaigns.”Bernardino reiterated a Buy on Vaxart along with a $3 price target, which is right in line with where shares are currently trading after this week's double-digit jump. (To watch Bernardino’s track record, click here)Over the last 3 months, no other analysts have published a review regarding Vaxart’s prospects. Based on Bernardino’s assessment, Vaxart has a Moderate Buy consensus rating. (See Vaxart stock analysis on TipRanks)
Shareholders in Vaxart, Inc. (NASDAQ:VXRT) may be thrilled to learn that the analysts have just delivered a major...
Shares of Kindred Biosciences and Vaxart popped Wednesday after the drugmakers inked a manufacturing deal for a coronavirus vaccine tablet. Aldeyra is also planning to test a treatment.
Professor of Medicine at Yale and Director of The Yale New Haven Hospital Center for Outcomes Research and Evaluation Dr. Harlan Krumholz joins Yahoo Finance’s Seana Smith to discuss Moderna’s recent headway in an early-stage coronavirus vaccine trial.
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
NEW YORK, April 27, 2020 -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Vaxart, Inc. (NASDAQ:.
Trump revealed the newest plans to develop vaccine, but later said the country will make a comeback with or without it. Board Certified Specialist in Preventive Medicine & Public Health Dr. David Katz joins Yahoo Finance’s Seana Smith to discuss.
Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.
The company released preliminary first-quarter results.
At last, the moment we have all been waiting for. The U.S. and some other countries are beginning to ease COVID-19 restrictions and draft exit strategies, but the battle against the deadly virus is far from over. Healthcare organizations have been working around the clock to advance a vaccine capable of taking down this formidable threat to public health, and while achieving this goal won’t be easy, one biotech company is pushing forward.Vaxart’s (VXRT) progress in its coronavirus (CoV) vaccine program has been nothing short of impressive, and the stock surged whopping 750% year-to-date. This hasn’t escaped the attention of H.C. Wainwright’s Vernon Bernardino, and the five-star analyst is even more optimistic after speaking with senior management regarding the company’s progress with its coronavirus (CoV) vaccine development program. Bernardino stated, “We gained confidence that Vaxart’s relationship with Emergent BioSolutions positions the company with strong vaccine development and manufacturing capabilities, and with $29.9 million in cash on hand as of March 31, 2020, and preliminary guidance for $2.8 million in royalty revenues in 1Q20, we remain favorable on our full-year projection of $11.6 million.”It should be noted that preclinical results have already been promising, with several of its vaccine candidates generating immune responses in all tested animals after a single dose. “While these are early results, the results in all five vaccine candidates in development demonstrate significant progress toward identification of a lead candidate for clinical testing...we believe the mucosal and systemic immunity observed, coupled with its oral, room temperature-stable tablet form, could offer logistical advantages over injectables during pandemic vaccination campaigns,” Bernardino commented.The news gets even better as the Biomedical Advanced Research and Development Authority (BARDA) recently awarded Moderna a $483 million grant to support the development of its messenger RNA (mRNA)-based vaccine candidate against SARS-CoV-2, mRNA-1273. Bernardino argues that this bodes well for VXRT as it could signal potential funding activities for other companies with vaccine candidates. He added, “Therefore, based on our belief that Vaxart could realize a long-term funding option from BARDA to further its own CoV vaccine development program in the next 3-6 months.”In line with his bullish approach, Bernardino kept a Buy rating on the stock. Adding to the good news, the analyst bumped up the price target from $3 to $7. Should this target be met, a twelve-month gain of 133% could be in the cards. (To watch Bernardino’s track record, click here)Looking at the consensus breakdown, the rest of the Street has been quiet when it comes to VXRT. Bernardino is the only analyst that has published a review recently.To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
“All our COVID-19 vaccine constructs were highly immunogenic in preclinical testing, and we are taking the candidate forward that is expected to generate the broadest immune response in humans,” said Sean Tucker, Ph.D., chief scientific officer of Vaxart. In January 2020, Vaxart initiated a program to develop a COVID-19 vaccine based on its VAASTTM oral vaccines platform.
During Vaxart's (VXRT) upcoming Q1 earnings call, investor focus will be on the company's progress with its oral vaccine candidates against SARS CoV-2.
Clinical Professor of Epidemiology at NYU School of Global Public Health Dr. Robyn Gershon joins Yahoo Finance’s Seana Smith to discuss the latest coronavirus developments as more states gear up to implement reopening plans.
Emergent's (EBS) earnings and revenues surpass estimates in the first quarter of 2020. The company reaffirms its guidance for the ongoing year.